Qilu Pharmaceuticals

Company snapshot

Established in 1958 and headquartered in Jinan, China, Qilu Pharmaceuticals is a large and comprehensive pharmaceutical company specializing in R&D, manufacture, sales and international trade of both APIs and drug products.

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Qilu Pharmaceuticals. Not investment advice.

• What is Qilu Pharmaceuticals?

  Qilu Pharmaceutical (Hainan) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Atopic Dermatitis, COVID-19. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrial

• Is Qilu Pharmaceuticals publicly traded?

  Qilu Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Qilu Pharmaceuticals develop or market?

  We link 4 drug profile(s) where Qilu Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/qilu-pharma-spain-s-l#company-drugs.

• What are the latest developments for Qilu Pharmaceuticals?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Qilu Pharmaceuticals focus on?

  Qilu Pharmaceuticals focuses on Atopic Dermatitis, COVID-19 based on our analysis of their pipeline programs and drug development activities.